Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab and Niraparib in Advanced Penile Cancer
NCT05526989Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, niraparib in penile carcinoma, sponsored by Moffitt Cancer Center. Started Dec 2022; status: recruiting.
02
Drugs
dostarlimabniraparib
03
Conditions
penile carcinoma
Beyond the preview
Go deeper on NCT05526989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526989.